BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21041376)

  • 1. Health care utilization and mortality among elderly patients with myelodysplastic syndromes.
    Lindquist KJ; Danese MD; Mikhael J; Knopf KB; Griffiths RI
    Ann Oncol; 2011 May; 22(5):1181-1188. PubMed ID: 21041376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.
    Zeidan AM; Wang R; Davidoff AJ; Ma S; Zhao Y; Gore SD; Gross CP; Ma X
    Cancer; 2016 May; 122(10):1598-607. PubMed ID: 26970288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
    Dodillet H; Kreuzer KA; Monsef I; Skoetz N
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia.
    Kako S; Nakasone H; Endo H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Kimura S; Okuda S; Yamazaki R; Oshima K; Tanihara A; Nishida J; Usuki K; Kanda Y
    Hematol Oncol; 2012 Jun; 30(2):82-8. PubMed ID: 21692099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients.
    Yabe M; Medeiros LJ; Tang G; Wang SA; P Patel K; Routbort M; Bhagat G; Bueso-Ramos CE; Jorgensen JL; Luthra R; Chen W; Muzzafar T; Kanagal-Shamanna R; Khoury JD; Daneshbod Y; Davanlou M; Li S; Young KH; Miranda RN
    Hum Pathol; 2016 Apr; 50():109-17. PubMed ID: 26997444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
    Tatarelli C; Piccioni AL; Maurillo L; Naso V; Battistini R; D'Andrea M; Criscuolo M; Nobile C; Villivà N; Mancini S; Neri B; Breccia M; Fenu S; Buccisano F; Voso MT; Latagliata R; Aloe Spiriti MA
    Ann Hematol; 2014 Aug; 93(8):1413-20. PubMed ID: 24647684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of survival gains in myelodysplastic syndromes.
    MacEwan JP; Yin W; Kaura S; Khan ZM
    Am J Manag Care; 2017 Jan; 23(1):e10-e15. PubMed ID: 28141936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes: incidence and survival in the United States.
    Ma X; Does M; Raza A; Mayne ST
    Cancer; 2007 Apr; 109(8):1536-42. PubMed ID: 17345612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.
    Breccia M; Latagliata R; Cannella L; Carmosino I; Santopietro M; Loglisci G; Federico V; Alimena G
    Leuk Lymphoma; 2010 May; 51(5):783-8. PubMed ID: 20302387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.
    Zandberg DP; Huang TY; Ke X; Baer MR; Gore SD; Smith SW; Davidoff AJ
    Haematologica; 2013 Apr; 98(4):584-90. PubMed ID: 23144192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy.
    Smith BD; Mahmoud D; Dacosta-Byfield S; Rosen VM
    Leuk Lymphoma; 2014 May; 55(5):1119-25. PubMed ID: 23841504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database.
    Fletcher SA; Cronin AM; Zeidan AM; Odejide OO; Gore SD; Davidoff AJ; Steensma DP; Abel GA
    Cancer; 2016 Apr; 122(8):1209-15. PubMed ID: 26914833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
    Vijenthira A; Premkumar D; Callum J; Lin Y; Wells RA; Chodirker L; Lenis M; Mamedov A; Buckstein R
    Leuk Res; 2019 Jan; 76():76-81. PubMed ID: 30580105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
    Rojas SM; Díez-Campelo M; Luño E; Cabrero M; Pedro C; Calabuig M; Nomdedeu B; Cedena T; Arrizabalaga B; García M; Cerveró C; Collado R; Azaceta G; Ardanaz MT; Muñoz JA; Xicoy B; Rodríguez MJ; Bargay J; Morell MJ; Simiele A; del Cañizo C
    Leuk Res; 2014 Mar; 38(3):304-9. PubMed ID: 24333115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis.
    Kim KJ; Kwok SK; Park YJ; Kim WU; Cho CS
    Int J Rheum Dis; 2012 Feb; 15(1):86-94. PubMed ID: 22324951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.